DelMar Pharmaceuticals Inc (DMPI)

1.40
NASDAQ : Health Care
Prev Close 1.26
Day Low/High 1.25 / 1.43
52 Wk Low/High 1.25 / 7.54
Avg Volume 135.60K
Exchange NASDAQ
Shares Outstanding 13.46M
Market Cap 16.96M
EPS -0.30
P/E Ratio 1.48
Div & Yield N.A. (N.A)

Latest News

DelMar Pharmaceuticals Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman

DelMar Pharmaceuticals Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman

Company Adopts Omnibus Equity Incentive Plan and Policy to Better Align with Shareholder Values and Facilitate Growth

DelMar Pharmaceuticals Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Study is currently enrolling MGMT-unmethylated Avastin (bevacizumab)-naive recurrent GBM patients at the University of Texas MD Anderson Cancer Center

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's how to trade five stocks that are ready to break out and trade higher from current levels.

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

Biotech investors have not had much to cheer about in 2016.

Shares of DelMar End Lower on First Day of Trading

Shares of DelMar End Lower on First Day of Trading

DelMar Pharmaceuticals enjoyed a bit of good news this week after its shares were uplisted to the Nasdaq Capital Market this week.

SeeThruEquity Issues Update On DelMar Pharmaceuticals, Inc.’s VAL-083 Clinical Trial

SeeThruEquity Issues Update On DelMar Pharmaceuticals, Inc.’s VAL-083 Clinical Trial

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar ...